They proposed that targeting palmitoyl-protein thioesterase 1 (PPT1) by hydroxychloroquine (HCQ) or genetic Ppt1 inhibition can enhance the anti-PD-1 Ab efficacy in melanoma, which may be mediated by lysosome dysfunction [149] (Table 1). The gene discussed is PPT1; the disease is melanoma.